BRAF Rabbit Polyclonal Antibody

CAT#: TA366788

BRAF rabbit polyclonal antibody

Product Images

Gel: 6%SDS-PAGE Lysate: 40 μg Lane: C2CL2 cell lysate Primary antibody: TA366788 (BRAF Antibody) at dilution 1/600 Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution Exposure time: 1 minute

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA366788 (BRAF Antibody) at dilution 1/50 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA366788 (BRAF Antibody) at dilution 1/50, treated with synthetic peptide. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using TA366788 (BRAF Antibody) at dilution 1/50 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using TA366788 (BRAF Antibody) at dilution 1/50, treated with synthetic peptide. (Original magnification: ×200)

Show all 5 images

Specifications

Product Data

• Applications: IHC, WB
• Recommended Dilution: WB: 500-2000
  WB positive control: C2CL2 cell lysate
  IHC: 50-200
  Positive control: Human liver cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human, Mouse
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Synthetic peptide of human BRAF
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Predicted Protein Size: 85 kDa
• Database Link:
  UniProt ID P15056
• Background: This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome.